PPARA and Alzheimer disease: Fenofibrate (an agonist of PPARα) also showed therapeutic effects on the amyloidogenic processing of APP through the PPARα/PI3K pathway in a transgenic mouse model of AD, which overexpresses APP/PS1 [27].